Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering
July 28, 2023 at 08:13 AM EDT
Biogen's all-cash deal is a rare-disease play.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|